Kura Oncology, Inc. (KURA)
10.60
+0.08
(+0.76%)
USD |
NASDAQ |
Oct 09, 16:00
10.60
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Cash from Operations (Quarterly) : -62.55M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -62.55M |
| March 31, 2026 | -85.85M |
| December 31, 2025 | 117.27M |
| September 30, 2025 | -80.63M |
| June 30, 2025 | -28.78M |
| March 31, 2025 | -71.93M |
| December 31, 2024 | 269.13M |
| September 30, 2024 | -43.44M |
| June 30, 2024 | -42.53M |
| March 31, 2024 | -48.84M |
| December 31, 2023 | -34.31M |
| September 30, 2023 | -29.03M |
| June 30, 2023 | -25.62M |
| March 31, 2023 | -35.87M |
| December 31, 2022 | -26.53M |
| September 30, 2022 | -21.01M |
| June 30, 2022 | -30.34M |
| March 31, 2022 | -32.18M |
| December 31, 2021 | -23.37M |
| September 30, 2021 | -24.59M |
| June 30, 2021 | -28.07M |
| March 31, 2021 | -28.52M |
| December 31, 2020 | -18.31M |
| Date | Value |
|---|---|
| September 30, 2020 | -16.97M |
| June 30, 2020 | -14.73M |
| March 31, 2020 | -19.82M |
| December 31, 2019 | -13.93M |
| September 30, 2019 | -12.14M |
| June 30, 2019 | -14.43M |
| March 31, 2019 | -14.25M |
| December 31, 2018 | -10.21M |
| September 30, 2018 | -13.00M |
| June 30, 2018 | -12.59M |
| March 31, 2018 | -12.85M |
| December 31, 2017 | -7.474M |
| September 30, 2017 | -6.235M |
| June 30, 2017 | -6.11M |
| March 31, 2017 | -8.622M |
| December 31, 2016 | -6.738M |
| September 30, 2016 | -5.472M |
| June 30, 2016 | -5.825M |
| March 31, 2016 | -7.314M |
| December 31, 2015 | -5.605M |
| September 30, 2015 | -4.43M |
| June 30, 2015 | -3.767M |
| March 31, 2015 | -4.123M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Fortress Biotech, Inc. | -59.28M |
| Spero Therapeutics, Inc. | -5.355M |
| Gossamer Bio, Inc. | -41.39M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 92.21M |
| Cash from Financing (Quarterly) | 1.499M |
| Free Cash Flow | -117.43M |
| Free Cash Flow Per Share (Quarterly) | -0.7113 |
| Free Cash Flow to Equity (Quarterly) | -63.39M |
| Free Cash Flow to Firm (Quarterly) | -62.86M |
| Free Cash Flow Yield | -12.55% |